Takeda oncology chief proposes $940K share sale
A prior 50,012-ADS sale is described as satisfying tax obligations in connection with vesting effective July 13, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Takeda Pharmaceutical Company Limited is identified as the issuer in Teresa Bitetti’s notice proposing a sale of 46,609 American Depositary Shares (ADSs), with an aggregate market value of $940,103.53 and an approximate sale date of November 1, 2026. Bitetti, President, Global Oncology Business Unit, previously sold 50,012 ADSs on August 10, 2026, for $855,205.20. The notice says that sale was conducted to satisfy tax obligations in connection with share vesting effective July 13, 2026.
Key Figures
Key Terms
Restricted Stock Unit Awards technical
aggregate market value financial
Rule 144 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many TAK ADSs does Teresa Bitetti propose to sell?
Why did Teresa Bitetti sell TAK ADSs in August 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.